RxDoctor Payments Data

Erica Adams

Family · Yanceyville, NCNPI 1346729985

Payments from drug & device makers

$1,235in general payments, 2019–2025

Across 76 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$342
  • Merck$298
  • Otsuka America Pharmaceutical, Inc.$110
  • Vanda Pharmaceuticals Inc.$64
  • Pfizer$52
  • Exact Sciences$47
  • plus $321 from 12 others

What the payments were for

  • Food & beverage$1,235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,235 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$29,555
Medicare patients
85
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$55,148
EliquisApixaban79$47,500
MounjaroTirzepatide31$32,360
JardianceEmpagliflozin14$24,877
FarxigaDapagliflozin Propanediol18$20,574
TrulicityDulaglutide20$19,355
InvokanaCanagliflozin16$13,977
Breo ElliptaFluticasone/Vilanterol21$8,655
LinzessLinaclotide16$8,354
XareltoRivaroxaban13$8,131
Spiriva HandihalerTiotropium Bromide13$6,699
JanumetSitagliptin Phos/Metformin Hcl11$5,191
MyrbetriqMirabegron12$5,183
Humalog Kwikpen U-200Insulin Lispro11$4,391
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$3,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$14$51,71551 claims
PfizerEliquis$52$47,50079 claims
GSKBreo Ellipta$28$8,65521 claims
AbbVieLinzess$342$8,35416 claims
MerckJanumet$298$5,19111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.

Other family in Yanceyville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →